United States Radiodermatitis Market Insights Forecasts to 2033

• The U.S. Radiodermatitis Market Size was valued at USD 320.5 Million in 2023.
• The Market Size is Growing at a CAGR of 5.2% from 2023 to 2033
• The U.S. Radiodermatitis Market Size is Expected to reach USD 531.9 Million by 2033

The United States Radiodermatitis Market is anticipated to exceed USD 531.9 Million by 2033, growing at a CAGR of 5.2% from 2023 to 2033. The growing incidence of cancer, advancements in techniques of radiation therapy, and the development of new treatment options are driving the growth of the radiodermatitis market in the US.      

Market Overview

Radiodermatitis is the common side effect of radiation therapy, which primarily affects patients receiving treatment for vulvar and breast cancer. 95.0% of cancer patients undergoing radiation therapy are estimated to develop radiodermatitis, which is characterised by erythema and dry/moist desquamation. Radiation dermatitis is becoming more common as a result of the growing application of radiation therapy brought about by targeted cancer treatment and standardised treatment plans amongst various facilities. Effective prevention methods are crucial, as anticipated numbers for 2024 show that 2,032 people will experience radiodermatitis linked to vulvar cancer and about 238,184 patients will experience radiodermatitis connected to breast cancer. The shift towards more specialised and potent therapies, with a concentration on topical pharmaceuticals, dressings, and oral medications, reflects the growing recognition and commitment of IRCs to provide patients with all-encompassing treatment, including management of radiodermatitis.

Report Coverage

This research report categorizes the market for the US radiodermatitis market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States radiodermatitis market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the US radiodermatitis market.

Driving Factors

There is a rising number of patients experiencing radiodermatitis as a side effect of radiation treatment for cancer treatment. Thus, the prevalence of cancer is significantly contributing to driving the market growth. The development of new radiodermatitis therapies, such as topical creams, dressings, and oral drugs, has expanded the market growth. The growing awareness about the importance of managing radiodermatitis among healthcare professionals and patients is propelling the market. Further, the evolution of radiation therapy techniques is also contributing to market growth. In addition, the collaborations and partnerships among healthcare providers, researchers, and pharmaceutical companies are also contributing to driving the market.

Restraining Factors

The market expansion for radiation dermatitis is being hampered by the growing use of modern radiation treatments, including intensity-modulated radiation therapy (IMRT) and proton therapy, which reduce the risk for radiation dermatitis.

Market Segmentation

The United States Radiodermatitis Market share is classified into product, distribution channel, and facility type.

• The topical segment is expected to grow at the fastest CAGR during the forecast period.

The United States radiodermatitis market is segmented by product into topical and dressings. Among these, the topical segment is expected to grow at the fastest CAGR during the forecast period. The topical product formulations such as creams, ointments, and gels are available for radiodermatitis treatment and prevention by reducing inflammation and promoting healing. Major pharmaceutical companies are launching the new topical cream formulation products which is anticipated to drive market growth. 

• The retail pharmacies segment dominated the US radiodermatitis market with the largest market share in 2023.       

Based on the distribution channel, the U.S. radiodermatitis market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the retail pharmacies segment dominated the US radiodermatitis market with the largest market share in 2023. Pharmacist-led treatments in retail settings have been shown to dramatically enhance patient outcomes for radiodermatitis, according to a 2020 study published in the Journal of the American Pharmacists Association. The accessibility of necessary medications in retail pharmacies upsurges the market demand in the retail pharmacies segment.

• The independent radiotherapy centers segment held the largest revenue share of the US radiodermatitis market during the forecast period.

Based on the facility type, the U.S. radiodermatitis market is divided into hospital-based radiotherapy centers and independent radiotherapy centers. Among these, the independent radiotherapy centers segment held the largest revenue share of the US radiodermatitis market during the forecast period. A rising number of centres, including IRCs, are putting more emphasis on enhancing treatment protocols and quality of care. This is because it is recognised that over half of radiation therapy patients get radiodermatitis at some point during their treatment. A strong emphasis on managing the side effects of radiation therapy, such as radiodermatitis, leads to driving the segmental growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the U.S. radiodermatitis market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Smith & Nephew
• Convatec, Inc.
• 3M
• Stratpharma AG
• Molnlycke Health Care AB
• Alliqua BioMedical
• BMG Pharma spA
• Derma Sciences, Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In April 2024, Mölnlycke, a world leading MedTech company specialising in wound care and wound management, announced it had signed an agreement to acquire P.G.F. Industry Solutions GmbH, the Austrian manufacturer of Granudacyn wound cleansing and moisturising solutions.

• In January 2023, Smith+Nephew, the global medical technology company, announced that it has completed the acquisition of CartiHeal, the developer of Agili-C, a novel sports medicine technology for cartilage regeneration in the knee.

• In January 2023, Convatec announced the US launch of ConvaFoam, a family of advanced foam dressings designed to address the needs of healthcare providers and their patients. ConvaFoam can be used on a spectrum of wound types at any stage of the wound journey, making it the simple dressing choice for wound management and skin protection.

Market Segment

This study forecasts revenue at U.S., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United States Radiodermatitis Market based on the below-mentioned segments:

US Radiodermatitis Market, By Product

• Topical
• Dressings

US Radiodermatitis Market, By Distribution Channe

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

US Radiodermatitis Market, By Facility Type

• Hospital-based Radiotherapy Centers
• Independent Radiotherapy Centers